AstraZeneca's Calquence Product Approved in China for Leukaemia Treatment
04 September 2023 - 8:45AM
Dow Jones News
By Joe Hoppe
AstraZeneca said its Calquence product has been approved in
China for the treatment of adults with leukaemia.
The Anglo-Swedish pharma giant said Monday the product has been
approved for the treatment of patients with chronic lymphocytic
leukaemia, or CLL--the most prevalent type of leukaemia across the
globe--or small lymphocytic lymphoma, or SLL, assuming they have
received at least one prior therapy.
The approval by the National Medical Products Administration was
based on positive results from two clinical trials, one global and
one local. The latter trial showed an 83.3% overall response rate
in Chinese patients treated with Calquence.
Calquence is approved for the treatment of CLL and SLL in the
U.S., CLL in the European Union and other countries around the
world, and approved in Japan for relapsed CLL and SLL.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
September 04, 2023 02:30 ET (06:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
